Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Want to cut your energy bills? Here’s how five experts are doing it 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
NEW YORK, March 21, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased HeartWare International, Inc. (Nasdaq:HTWR) securities between June 10, 2014 and January 11, 2016.
Click here to learn about the case: http://docs.wongesq.com/HTWR-Info-Request-Form-1018. There is no cost or obligation to you.
The complaint alleges that during the Class Period, HeartWare and certain of its senior executives made false and misleading statements and omitted material information. In particular, it is alleged that after the U.S. Food and Drug Administration issued a Warning Letter identifying numerous manufacturing and other regulatory failures at the Company’s sole manufacturing facility, Defendants falsely assured investors that the Company had addressed those problems, and that these concerns therefore posed no risk to the clinical trials or timely approval of MVAD, a pump that HeartWare is developing.
Following a series of disclosures regarding adverse effects in certain clinical trial patients, shares of HeartWare have declined from a close of $87.73 per share on June 25, 2014, to a close of just $34.50 per share on January 22, 2016.
If you suffered a loss in HeartWare you have until March 22, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/HTWR-Info-Request-Form-1018.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigation involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
